Immunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: A randomized controlled Phase 1 study

Vaccine

Volumn 32, Issue 48, 2014, Pages 6469-6477

  Gordon, David ^a   Kelley, Peter ^a   Heinzel, Susanne ^b   Cooper, Peter ^b,d,e   Petrovsky, Nikolai ^b,c  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b VAXINE PTY LTD   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

^d The Australian National University   (Australia)

^e Australian National University   (Australia)

Author keywords

Adjuvant; Advax; Clinical trial; Delta inulin; Hepatitis B; Human; Phase 1; Vaccine

Indexed keywords

ADVAX; C REACTIVE PROTEIN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOLOGICAL ADJUVANT; INULIN; POLYSACCHARIDE; RECOMBINANT HEPATITIS B VACCINE; SERUM GLOBULIN; UNCLASSIFIED DRUG; HEPATITIS B VACCINE; VIRUS ANTIBODY;

ADJUVANT THERAPY; ADULT; ANTIBODY TITER; ARTICLE; ASYMPTOMATIC INFECTION; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE SWELLING; LYMPHOCYTE PROLIFERATION; MALE; MYALGIA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; SKIN REDNESS; VACCINATION; VIRUS INFECTION; VISUAL ANALOG SCALE; ANALOGS AND DERIVATIVES; AUSTRALIA; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; SINGLE BLIND PROCEDURE; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES, VIRAL; AUSTRALIA; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; INULIN; MALE; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84908651646     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.09.034     Document Type: Article

References (53)

1. WHO World Health Organization Fact Sheet 204 2014, available at: http://wwwwhoint/mediacentre/factsheets/fs204/en/2008 [Revised August 2008].
2. Diminsky D., Schirmbeck R., Reimann J., Barenholz Y. Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicity. Vaccine 1997, 15(April-May (6-7)):637-647.
3. Andre F.E. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 1989, 87(September (3A)):14S-20S.
4. Keating G.M., Noble S. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs 2003, 63(10):1021-1051.
5. Fabrizi F., Dixit V., Messa P., Martin P. Hepatitis B virus vaccine in chronic kidney disease: improved immunogenicity by adjuvants? A meta-analysis of randomized trials. Vaccine 2012, 30(March (13)):2295-2300.
6. Bertoletti A., Gehring A. Therapeutic vaccination and novel strategies to treat chronic HBV infection. Expert Rev Gastroenterol Hepatol 2009, 3(October (5)):561-569.
7. Pan H.X., Zeng Y., Song X.F., Zhang Y.J., Xu K., Liang Z.L., et al. Immune response to hepatitis B vaccine with high antigen content in non-responders after standard primary vaccination in Chinese adults. Vaccine 2014, 32(June (29)):3706-3712.
8. Milich D.R., Thornton G.B., Neurath A.R., Kent S.B., Michel M.L., Tiollais P., et al. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science 1985, 228(June (4704)):1195-1199.
9. Levie K., Gjorup I., Skinhoj P., Stoffel M. A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults. Scand J Infect Dis 2002, 34(8):610-614.
10. Tong N.K., Beran J., Kee S.A., Miguel J.L., Sanchez C., Bayas J.M., et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 2005, 68(November (5)):2298-2303.
11. Cooper C.L., Davis H.L., Morris M.L., Efler S.M., Adhami M.A., Krieg A.M., et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004, 24(November (6)):693-701.
12. Heyward W.L., Kyle M., Blumenau J., Davis M., Reisinger K., Kabongo M.L., et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age. Vaccine 2013, 31(November (46)):5300-5305.
13. Cooper P.D., Petrovsky N. Delta inulin: a novel, immunologically active, stable packing structure comprising beta-d-[2→1] poly(fructo-furanosyl) alpha-d-glucose polymers. Glycobiology 2011, 21(May (5)):595-606.
14. Cooper P.D., Barclay T.G., Ginic-Markovic M., Petrovsky N. The polysaccharide inulin is characterized by an extensive series of periodic isoforms with varying biological actions. Glycobiology 2013, 23(October (10)):1164-1174.
15. Cooper P.D., Barclay T.G., Ginic-Markovic M., Gerson A.R., Petrovsky N. Inulin isoforms differ by repeated additions of one crystal unit cell. Carbohydr Polym 2014, 103(March):392-397.
16. Honda-Okubo Y., Saade F., Petrovsky N. Advax, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses. Vaccine 2012, 30(August (36)):5373-5381.
17. Layton R.C., Petrovsky N., Gigliotti A.P., Pollock Z., Knight J., Donart N., et al. Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets. Vaccine 2011, 29(August (37)):6242-6251.
18. Lobigs M., Pavy M., Hall R.A., Lobigs P., Cooper P., Komiya T., et al. An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses. J Gen Virol 2010, 91(June (Pt 6)):1407-1417.
19. Larena M., Prow N.A., Hall R.A., Petrovsky N., Lobigs M. JE-ADVAX vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of CD8+ T cells and pre-exposure neutralizing antibody. J Virol 2013, 87(April (8)):4395-4402.
20. Petrovsky N., Larena M., Siddharthan V., Prow N.A., Hall R.A., Lobigs M., et al. An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody. J Virol 2013, 87(September (18)):10324-10333.
21. Cristillo A.D., Ferrari M.G., Hudacik L., Lewis B., Galmin L., Bowen B., et al. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. J Gen Virol 2011, 92(January (Pt 1)):128-140.
22. Feinen B., Petrovsky N., Verma A., Merkel T.J. Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant. Clin Vaccin Immunol 2014, 21(April (4)):580-586.
23. Saade F., Honda-Okubo Y., Trec S., Petrovsky N. A novel hepatitis B vaccine containing Advax, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. Vaccine 2013, 31(15):1999-2007. January, Apr 8.
24. Ioshimoto L.M., Rissato M.L., Bonilha V.S., Miyaki C., Raw I.I., Granovski N. Safety and immunogenicity of hepatitis B vaccine ButaNG in adults. Rev Inst Med Trop Sao Paulo 1999, 41(May (3)):191-193.
25. Lyons A.B., Parish C.R. Determination of lymphocyte division by flow cytometry. J Immunol Methods 1994, 171(May (1)):131-137.
26. Moher D., Hopewell S., Schulz K.F., Montori V., Gotzsche P.C., Devereaux P.J., et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg 2012, 10(1):28-55.
27. Marnell L., Mold C., Du Clos T.W. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol 2005, 117(November (2)):104-111.
28. Gotze O., Muller-Eberhard H.J. The c3-activator system: an alternate pathway of complement activation. J Exp Med 1971, 134(September (3)):90-108.
29. Colafrancesco S., Perricone C., Priori R., Valesini G., Shoenfeld Y. Sjogren's syndrome: another facet of the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). J Autoimmun 2014, 51(June):10-16.
30. Shaw C.A., Tomljenovic L. Aluminum in the central nervous system (CNS): toxicity in humans and animals, vaccine adjuvants, and autoimmunity. Immunol Res 2013, 56(July (2-3)):304-316.
31. Cerpa-Cruz S., Paredes-Casillas P., Landeros Navarro E., Bernard-Medina A.G., Martinez-Bonilla G., Gutierrez-Urena S. Adverse events following immunization with vaccines containing adjuvants. Immunol Res 2013, 56(July (2-3)):299-303.
32. Ahmed S.S., Schur P.H., MacDonald N.E., Narcolepsy S.L. 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. J Autoimmun 2014, 50(May):1-11.
33. Arguedas A., Soley C., Abdelnour A., Sales V., Lindert K., Della Cioppa G., et al. Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. Hum Vaccin 2011, 7(January (1)):58-66.
34. Vandepapeliere P., Horsmans Y., Moris P., Van Mechelen M., Janssens M., Koutsoukos M., et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 2008, 26(March (10)):1375-1386.
35. Langermans J.A., Schmidt A., Vervenne R.A., Birkett A.J., Calvo-Calle J.M., Hensmann M., et al. Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaques. Vaccine 2005, 23(September (41)):4935-4943.
36. Wiegand J., Meya S., Schlaphoff V., Manns M.P., Mossner J., Wedemeyer H., et al. HBV-specific T-cell responses in healthy seronegative sexual partners of patients with chronic HBV infection. J Viral Hepat 2010, 17(September (9)):631-639.
37. Bauer T., Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 2006, 24(January (5)):572-577.
38. Petrovsky N., Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004, 82(October (5)):488-496.
39. Panitch H., Ciccone C. Induction of recurrent experimental allergic encephalomyelitis with myelin basic protein. Ann Neurol 1981, 9(May (5)):433-438.
40. Sabbatini P.J., Ragupathi G., Hood C., Aghajanian C.A., Juretzka M., Iasonos A., et al. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin Cancer Res 2007, 13(July (14)):4170-4177.
41. Drane D., Maraskovsky E., Gibson R., Mitchell S., Barnden M., Moskwa A., et al. Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers. Hum Vaccin 2009, 5(March (3)):151-157.
42. Batista-Duharte A., Lindblad E.B., Oviedo-Orta E. Progress in understanding adjuvant immunotoxicity mechanisms. Toxicol Lett 2011, 203(June (2)):97-105.
43. Cooper C., Mackie D. Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV safety and efficacy. Expert Rev Vaccin 2011, 10(April (4)):417-427.
44. Rendi-Wagner P., Kundi M., Stemberger H., Wiedermann G., Holzmann H., Hofer M., et al. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine 2001, 19(February (15-16)):2055-2060.
45. Gherardi R.K., Coquet M., Cherin P., Authier F.J., Laforet P., Belec L., et al. Macrophagic myofasciitis: an emerging entity. Groupe d'Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l'Association Francaise contre les Myopathies (AFM). Lancet 1998, 352(August (9125)):347-352.
46. Vera-Lastra O., Medina G., Cruz-Dominguez Mdel P., Jara L.J., Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome): clinical and immunological spectrum. Expert Rev Clin Immunol 2013, 9(April (4)):361-373.
47. Coulson E.J., Stevens H. Quantitative studies in anaphylaxis; effect of the alum adjuvant and route of administration on the sensitizing dose. J Immunol 1949, 61(February (2)):119-123.
48. Terhune T.D., Deth R.C. How aluminum adjuvants could promote and enhance non-target IgE synthesis in a genetically-vulnerable sub-population. J Immunotoxicol 2013, 10(April-June (2)):210-222.
49. Garcia A., De Sanctis J.B. An overview of adjuvant formulations and delivery systems. APMIS: acta pathologica, microbiologica, et immunologica. Scandinavica 2014, 122(April (4)):257-267.
50. Barclay T., Ginic-Markovic M., Johnston M.R., Cooper P.D., Petrovsky N. Analysis of the hydrolysis of inulin using real time 1H NMR spectroscopy. Carbohydr Res 2012, 352(May):117-125.
51. Robson J.S., Ferguson M.H., Olbrich O., Stewart C.P. The determination of the renal clearance of inulin in man. Q J Exp Physiol 1949, 35(June (2)):111-134.
52. Shannon J.A., Smith H.W. The excretion of inulin, xylose and urea by normal and phlorizinized man. J Clin Invest 1935, 14(July (4)):393-401.
53. Gordon D.L., Sajkov D., Woodman R.J., Honda-Okubo Y., Cox M.M., Heinzel S., et al. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax polysaccharide adjuvant. Vaccine 2012, 30(August (36)):5407-5416.